Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients

Phase II Study of Bevacizumab and Vorinostat for Recurrent WHO Grade IV Malignant Glioma Patients

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01738646

Enrollment

Registered

2012-11-30

Start date

2013-01-31

Completion date

2016-02-29

Last updated

2017-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Brain Tumor, Malignant Glioma, Recurrent Glioblastoma Multiforme

Keywords

vorinostat, SAHA, bevacizumab, AVASTIN, malignant glioma, GBM, glioblastoma multiforme, brain tumor

Brief summary

It has been shown that bevacizumab has significant anti-tumor activity in patients with recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against malignant glioma and can enhance the action of both chemotherapy and anti-angiogenics. Patients will be treated with a combination of bevacizumab and vorinostat.

Detailed description

There is no effective therapy for patients with recurrent glioblastoma multiforme (GBM) hence such patients remain a major unmet need in oncology. The investigators have recently demonstrated that bevacizumab (BV), a humanized monoclonal antibody against vascular endothelial growth factor, has significant anti-tumor activity among recurrent glioblastoma multiforme patients. Vorinostat has modest anti-tumor activity against malignant glioma and can potentiate the action of both chemotherapy and anti-angiogenics. The current study is designed to evaluate the anti-tumor activity of vorinostat when combined with BV among recurrent glioblastoma multiforme patients.

Interventions

DRUGVorinostat

DRUGBevacizumab

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

* Age \> 18 years. * An interval of at least 4 weeks between prior surgical resection or one week from stereotactic biopsy. * An interval of at least 12 weeks from the end of prior radiotherapy unless there is a new area of enhancement consistent with recurrent tumor outside of the radiation field, or there is biopsy-proven tumor progression * An interval of at least 4 weeks from prior chemotherapy \[6 weeks for nitrosoureas, 1 week for daily administered chemotherapy (metronomic dosing)\] or investigational agent unless the patient has recovered from all anticipated toxicities associated with that therapy. * Eastern Cooperative Oncology Group (ECOG) 0-1. * Hematocrit ≥ 29%, hemoglobin ≥ 9, absolute neutrophil ≥1,500 cells/microliter, platelets ≥ 100,000 cells/microliters. * Serum creatinine, serum glutamic oxaloacetic transaminase(SGOT) and bilirubin \< 1.5 times upper limit of normal. * Signed informed consent approved by the Institutional Review Board prior to patient entry. * No evidence of hemorrhage on the baseline MRI or CT scan other than those that are stable grade 1. * If sexually active, patients will take contraceptive measures for the duration of the treatments. Medically acceptable contraceptives include: (1) surgical sterilization (such as a tubal ligation, hysterectomy, vasectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD).

Exclusion criteria

Disease-specific exclusions * More than 2 prior episodes of disease progression * Prior therapy with histone deacetylase inhibitors; valproic acid is not permitted and patients previously treated with valproic acid must be off valproic acid for at least 30 days prior to initiation of study medication * Prior bevacizumab therapy * Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids * Active infection requiring intravenous antibiotics * Severe hepatic insufficiency, active viral hepatitis or HIV infection * Requires therapeutic anti-coagulation with warfarin General medical exclusions Subjects meeting the following criteria are ineligible for study entry: * Inability to comply with study and/or follow-up procedures Bevacizumab-specific exclusions * Inadequately controlled hypertension (defined as systolic blood pressure \> 150 and/or diastolic blood pressure \> 100 mmHg on antihypertensive medications) * Any prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E) * History of myocardial infarction or unstable angina within 6 months prior to study enrollment * History of stroke or transient ischemic attack within 6 months prior to study enrollment * Significant vascular disease (e.g., aortic aneurysm, aortic dissection) * Symptomatic peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment * Serious, non-healing wound, ulcer, or bone fracture * Proteinuria at screening as demonstrated by either: * Urine protein:creatinine (UPC) ratio \>= 1.0 at screening OR * Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible). * Known hypersensitivity to any component of bevacizumab * Pregnant (positive pregnancy test) or lactating. Refuse the use of effective means of contraception (men and women) in subjects of child-bearing potential

Design outcomes

Primary

Measure	Time frame	Description
Six-month Progression-free Survival (PFS6)	6 months	The percentage of participants alive and progression-free at 6 months after the start of study treatment will be determined. Based on Response Assessment in Neuro-Oncology (RANO) criteria, progression is defined as a ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions; significant increase in T2/FLAIR; any new lesion; clear clinical deterioration not attributable to other causes apart from the tumor; failure to return for evaluation as a result of death or deteriorating condition; or clear progression of non-measurable disease. PFS6 will be calculated from the date study treatment started until the date of progression or death, or the date of last follow-up if participants are alive without progression. Kaplan-Meier methods will be used to estimate survival.

Secondary

Measure	Time frame	Description
Radiographic Response	3 Years	The percentage of participants with a complete or partial response as determined by modified Response Assessment in Neuro-Oncology (RANO) criteria will be determined. Complete Response (CR) is defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses) and accompanied by a stable or improving neurologic examination. Partial Response (PR) is defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids and accompanied by a stable or improving neurologic examination. Tumor assessments are done at baseline and the end of every second cycle (every 8 weeks) thereafter.
Percentage of Participants Who Experience Grade 3 or Greater, Treatment Related, Non-hematologic Toxicities.	2.7 Years	The percentage of participants who experience grade 3 or greater, treatment-related, non-hematologic toxicities will be calculated.
Median Progression-free Survival (PFS)	3 Years	Progression-free survival is defined as the time in months from the start of protocol treatment until the date of progression or death if death occurred before progression. If the participant is alive and progression-free, PFS will be censored at the date of last follow-up. Kaplan-Meier methods will be used to estimate progression-free survival.
Median Overall Survival (OS)	3 Years	Overall survival is defined as the time in months from the start of protocol treatment until the date of death, or the date of last follow-up if alive. Kaplan-Meier methods will be used to estimate overall survival.

Countries

United States

Participant flow

Pre-assignment details

48 participants signed consent. 8 participants are considered screen failures. 40 participants received treatment.

Participants by arm

Arm	Count
Vorinostat & Bevacizumab Patients will be administered bevacizumab every 2 weeks and vorinostat will be taken on days 1-7 and 15-21 of each 28-day cycle at 400 mg per day.	40
Total	40

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Still Receiving Treatment	2

Baseline characteristics

Characteristic	Vorinostat & Bevacizumab
Age, Continuous	52.4 years STANDARD_DEVIATION 11
Sex: Female, Male Female	16 Participants
Sex: Female, Male Male	24 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	40 / 40
serious Total, serious adverse events	12 / 40

Arm	Measure	Value (NUMBER)
Vorinostat & Bevacizumab	Radiographic Response	22.5 percentage of participants

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026